Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART

HIV Medicine

Volumn 3, Issue 1, 2002, Pages 21-27

  Stone, S F ^a,b   Price, P ^a,b   Keane, N M ^a,b   Murray, R J ^a   French, M A ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

HAART; HIV; IL 6; Immune restoration disease; Soluble IL 6 receptor

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PROTEINASE INHIBITOR;

ANAMNESIS; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CELL STIMULATION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE STATUS; INTERFERON PRODUCTION; LYMPHOCYTE COUNT; MALE; MONOCYTE; MONONUCLEAR CELL; OPPORTUNISTIC INFECTION; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SERODIAGNOSIS; SUPERNATANT; T LYMPHOCYTE; TREATMENT OUTCOME;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HIV; HIV INFECTIONS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-6; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6; RNA, VIRAL; STATISTICS, NONPARAMETRIC;

EID: 0036184719     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-2662.2001.00096.x     Document Type: Article

References (34)

1. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy
2. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy
3. Immunorestitution disease involving the innate and adaptive response
4. Immune reconstitution syndrome in human immuno-deficiency virus infection following effective antiretroviral therapy
5. Zidovudine induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients
6. Detection of subclinical Mycobacterium avium intracellulare complex infection in immunodeficient HIV-infected patients treated with zidovudine
7. Exacerbation of the inflammatory response to Mycobacterium tuberculosis after antiretroviral therapy
8. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS
9. Immunopathology as a result of highly active anti-retroviral therapy in HIV-1 infected patients
10. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor
11. Acute clinical hepatitis in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy
12. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An 'immune restoration disease'?
13. MHC haplotypes affect the expression of opportunistic infections in HIV patients
14. Complex of soluble human IL-6 receptor/IL-6 up-regulates expression of acute-phase proteins
15. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines
16. Infection with HIV is associated with elevated IL-6 levels and production
17. Human soluble IL-6 receptor: Its detection and enhanced release by HIV infection
18. Initial increase in blood CD4 (+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues
19. Impact of highly active antiretroviral therapy (HAART) on cytokine production and monocyte subsets in HIV-infected patients
20. Assessment of immune function by lymphoproliferation underestimates lymphocyte functional capacity in HIV patients treated with highly active antiretroviral therapy
21. Interleukin-6 receptor signalling. II. Bio-availability of interleukin-6 in serum
22. Tumor necrosis factor (TNF) system levels in human immunodeficiency Virus-infected patients during highly active antiretroviral therapy: Persistent TNF activation is associated with virologic and immunologic treatment failure
23. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic onset juvenile chronic arthritis
24. Proinflammatory cytokine and human immunodeficiency virus RNA levels during early Mycobacterium avium complex bacteremia in advanced AIDS
25. Elevated serum cytokines are associated with cytomegalovirus infection and disease in bone marrow transplant recipients
26. Immune dysfunction and immune restoration disease in HIV patients given highly active anti-retroviral therapy
27. Detection of infectious HIV in circulating monocytes from patients on prolonged antiretroviral therapy
28. Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6
29. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients
30. Successful treatment of Castleman's disease with HAART in two HIV-infected patients
31. Mucosal Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected patient
32. An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS
33. Inflammatory markers in men with angiographically documented coronary heart disease
34. Interleukin-6 stimulated LDL receptor gene expression via activation of sterol-responsive and Sp1 binding elements